Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rh-aFGF for nasal mucosa healing after ESS in chronic rhinosinusitis
ChiCTR2200066971Phase 4Recruiting
- Sponsor
- Shanghai East Hospital, School of Medicine, Tongji University
- Start
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of recombinant human acidic fibroblast growth factor in chronic rhinosinusitis (CRS) (2 arms), sponsored by Shanghai East Hospital, School of Medicine, Tongji University. Primary endpoints: Sino-Nasal Outcome Test-22 (SNOT-22) and Lund-Kennedy endoscopic score. Started Dec 2022; status: recruiting.
02
Drugs
recombinant human acidic fibroblast growth factor
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on ChiCTR2200066971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066971.